Owkin
Accelerating drug discovery and precision medicine through federated learning and multi-modal AI.
Accelerating the discovery of life-changing bioactive peptides through AI-driven molecular intelligence.
Nuritas is a pioneering AI biotechnology firm that leverages its proprietary 'Nuri' platform to identify and validate bioactive peptides from natural sources. By 2026, Nuritas has solidified its position as the global leader in the 'Dark Proteome' exploration, using deep learning to predict how specific peptide sequences interact with biological pathways. The technical architecture combines massive proprietary datasets with closed-loop laboratory automation, ensuring that AI predictions are immediately validated through in-vitro and in-vivo testing. Unlike traditional ingredient discovery, which relies on trial and error, the Nuritas Nuri engine utilizes high-resolution proteomics and neural networks to reduce discovery timelines from years to months. The platform focuses on high-impact areas such as muscle health (PeptiStrong), skin rejuvenation (PeptiYouth), and glucose management. For enterprise partners, Nuritas provides a complete R&D pipeline that spans from digital molecular screening to clinical-grade ingredient production, making it a critical infrastructure layer for the next generation of functional foods, supplements, and therapeutic cosmetics.
A deep-learning platform trained on the world's largest proprietary database of bioactive peptides.
Verified feedback from the global deployment network.
Post queries, share implementation strategies, and help other users.
Integration of AI predictions with robotic synthesis and testing for real-time model training.
Advanced proteomics used to identify hidden sequences in natural food sources.
Neural networks that simulate human biological responses to specific peptide sequences.
Combines genomic, proteomic, and metabolomic data to refine discovery targets.
Proprietary methods for mass-producing complex peptides at food-grade costs.
A quantitative ranking system for molecular candidates based on potency and safety.
Sarcopenia and muscle loss due to aging or inactivity.
Registry Updated:2/7/2026
Loss of collagen and skin elasticity.
Blood sugar spikes in pre-diabetic populations.